Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNAi therapeutics.
S&P 500 Movers
Range dropdown markets
Oil 73.58 0.77 1.06
All Times Eastern Latest News
Scroll up, scroll down
Toggle chart options
$ % Vol
Volume: 1.3M 65-Day Average: 777.33K
168% vs. Avg 187.94 Days Range 194.25, 117.58 52-Week Range 242.97
Recent Viewed Tickers
Float Shorted at 4.00%
Average Volume 777.33K
Number of Ratings 26 Ratings Full
MarketWatch Dow Jones
Alnylam Pharma Chairman Stepping Down
Jan. 5, 2023, at 4:44 p.m. ET
Biotech and Pharma Karuna's Schizophrenia Trial Data Are the 'Best Case Scenario’ for the Biotech Stock
August 8, 2022, 11:48 a.m. ET by Barron's
Biotech and Pharma: The bull market in biotech stocks is still going strong
Aug. 4, 2022, 9:41 AM ET by Barron's
Biotech and Pharma Alnylam Stock Rockets Half-Off Trial Results Give Hope for a Blockbuster
Aug. 3, 2022, 11:21 a.m. ET by Barron's
Stock of Alnylam jumps 57% after it shares positive news about its experimental RNAi treatment
Aug. 3, 2022, 8:17 a.m. ET by Jaimy Le
Biotech and Pharma add to litigation concerns for moderna stock
Mar. 18, 2022, 10:16 a.m. ET by Barron's
Alnylam Pharmaceuticals outperforms Oppenheimer
Nov. 1, 2021, 7:42 a.m. ET by Tomi Kilgore
Alnylam Pharmaceuticals upgrades to buy from UBS
Oct. 4, 2021, 9:39 a.m. ET by Tomi Kilgore
Biotech and Pharma Intellia Stocks Are Exploding Due to a Gene Editing Breakthrough
28th of June 2021, 10:39 a.m. ET by Barron's
Intellia is a good place to look for biotech and pharmaceutical gene editing data. This is how it made history.
28th of June 2021, 8:39 a.m. ET by Barron's
Biotech and Pharma Vir will Test Its Covid-19Antibody with Eli Lilly's, Recommending Shares
Jan. 27, 2021, 10:08 a.m. ET by Barron's
Alnylam Pharmaceuticals is downgraded at BMO Capital to market perform, from outperform
Jan. 25, 2021, 9:20 a.m. ET by Tomi Kilgore
Options: Get ready for the wild world of health-care stocks. How to Play Them.
Jan. 5, 2021, 6:00 a.m. ET by Barron's
Real Estate Blackstone's Deal for Lab Space of $3.45 billion Shows Boom in Life Sciences
Dec. 14, 2020, 3:51 p.m. ET by Barron's
Oppenheimer downgrades Alnylam Pharmaceuticals to outperform
August 11, 2020 at 7:54 AM ET by Tomi Kilgore
Health Drops Out as a Top Contestant in the Race to Obtain a NASH Drug
23.02.2020 at 11:02 a.m. ET by Barron's
Alnylam Pharmaceuticals' stock price target increased to $196, from $173 at BMO Kapital
20 at 8:38 AM, 2020 ET by Tomi Kilgore
J.P. Morgan downgrades Alnylam Pharmaceuticals to neutral from overweight
7, 2020 at 8:13 am. ET by Tomi Kilgore
These 23 companies are currently working on vaccines or treatments for coronavirus. Here's what we know.
6:50 p.m. ET by Jaimy Le
Other News Press Releases
Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals, Inc., a global, commercial-stage biopharmaceutical firm, engages in the development, commercialization, and discovery of RNAi therapeutics. ONPATTRO and GIVLAARI are its products. Phillip A., Phillip A., Thomas Tuschl and Phillip Zamore founded the company. Sharp was founded by Phillip A. Sharp on June 14, 2002. It is headquartered at Cambridge, MA.
Arrowhead Pharmaceuticals Corp. –0.53% $2.65B